From Our Thought Leaders

Building Biotech Development Strategies for an Uncertain Future

  Drug development is inherently uncertain, with scientific discoveries, manufacturing challenges, regulatory expectations and commercial priorities capable of reshaping a program at any stage. Rather than attempting to eliminate uncertainty, b... Read more

14 August, 2026 | Friday | Expert Opinion
Bone Biologics Advances Targeted Bone Regeneration with the NELL-1 Platform

    Bone Biologics is developing a targeted approach to bone regeneration through its proprietary NELL-1 platform, designed to address the limitations of conventional bone graft materials. In this interview with BioPharma Boardroom, Jef... Read more

10 August, 2026 | Monday | Interaction
Merck Raises 2026 Guidance After Strong Q2 Performance, Says CEO Kai Beckmann

Merck has reported strong financial results for the second quarter of 2026, driven by sustained growth across its Life Science and Electronics businesses. The company posted organic net sales growth of 4.1% and organic EBITDA pre growth of 9.3%, pr... Read more

07 August, 2026 | Friday | Company results
QIAGEN CEO Thierry Bernard Cites Growth Momentum as Q2 Results Top Expectations

Q2 2026 results: Net sales of $535 million unchanged compared with Q2 2025 on a reported basis and at constant exchange rates (CER), exceeding the outlook for an about 2% CER decline Growth pillars deliver about 5% CER growth, led by Sample... Read more

07 August, 2026 | Friday | Company results

Bio Finance

Veloxis Pharmaceuticals to Pay $46 Million to Resolve Envarsus XR Fraud Case

In a major healthcare fraud enforcement action, Veloxis Pharmaceuticals will pay over million and accept a stringent deferred prosecution agreement after admitting illegal conduct tied to Envarsus XR in a case brought by two leading qui t... Read more

17 August, 2026 | Monday | News
Basilea Secures Additional USD 30 Million BARDA Funding for Phase 3 Antifungal Program

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced  that the Biomedical Advanced Research and Develop... Read more

29 July, 2026 | Wednesday | News

Contract Services

PacBio Boosts Vega HiFi Sequencing Output by 50% with New SPRQ-Nx Chemistry

PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, announced the upcoming availability of SPRQ-Nx chemistry and an accompanying software update for its Vega systems. Together, the updates expand the range o... Read more

13 August, 2026 | Thursday | News
AGC Biologics Secures Multi-Year Commercial Manufacturing Agreement for Yokohama Facility

Reached a long-term business cooperation with a large pharmaceutical company to help it promote production licensing and commercial supervision and approval in major markets. Customers choose AGC Biologics Yokohama's new base to promote five com... Read more

30 July, 2026 | Thursday | News

BioPharma Video

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close